What is Vida Diagnostics?
Vida Diagnostics operates at the intersection of medical imaging and artificial intelligence, providing a sophisticated software suite that empowers physicians to improve patient outcomes. By transforming raw clinical data into actionable insights, the platform streamlines care coordination and enhances operational efficiency for large-scale healthcare providers. The company's focus on high-impact respiratory care has become increasingly relevant, particularly as clinical leadership seeks to integrate data-driven decision support into standard workflows for chronic disease management and acute respiratory challenges.
How much funding has Vida Diagnostics raised?
Vida Diagnostics has raised a total of $10.1M across 4 funding rounds:
Other Financing Round
$2.5M
Series B
$5.1M
Other Financing Round
$500K
Series C
$2M
Other Financing Round (2014): $2.5M with participation from Next Level Ventures
Series B (2016): $5.1M led by Rittenhouse Ventures, Iowa Seed Fund, Chartline Capital Management, and Next Level Ventures
Other Financing Round (2019): $500K supported by Iowa Innovation Acceleration Fund
Series C (2020): $2M featuring OSF Ventures
Key Investors in Vida Diagnostics
Next Level Ventures
A prominent Iowa-based investment firm managing over $400 million in assets, specializing in strategic capital ranging from seed to growth-stage for innovative companies.
Rittenhouse Ventures
A Philadelphia-based venture capital firm focused on early-stage technology businesses, providing tailored investments and strategic expertise to drive capital-efficient growth.
Chartline Capital Management
A B2B venture investor targeting enterprise and industrial technology companies, offering hands-on partnership and strategic support to help founders scale efficiently.
What's next for Vida Diagnostics?
With the recent influx of capital, Vida Diagnostics is well-positioned to accelerate its market penetration and deepen its technological moat. The company is expected to focus on expanding its diagnostic capabilities and enhancing its suite of visualization tools to meet the growing demand for precision medicine in respiratory health. As the firm scales, the strategic focus will likely shift toward broader integration with enterprise electronic health record systems, further embedding its intelligence platform into the clinical decision-making process. This phase of growth will be critical in maintaining its competitive edge as a leader in digital health innovation.
See full Vida Diagnostics company page
